R&D Rare Disease R&D: one step forward, but a long road ahead With over 40% of all medicines in the pipeline aimed at rare diseases, the future looks positive for increasing the number of treatments available.
News Rare diseases have tenfold higher impact on healthcare costs... A new study has suggested that the economic burden posed by rare diseases is around 10 times higher than for common "mass market" conditions.
Views & Analysis Why we need research into the mental health impact of a rare... Rare diseases impact between 3.5%-5.9% of the world’s population.
Views & Analysis Expediting innovation in the rare disease domain Rare diseases affect a fraction of the population – 450 million+ peop
Views & Analysis Rare disease insights from the patient community To help pharma companies understand what life is really like for patients with a rare disease, a new resource has been released to coincide with Rare Disease Day 2021.
Views & Analysis Building a better future for people with rare diseases in al... How has rare disease care changed over the last few years? And what might we expect from the next five?
Sales & Marketing Biotech is back, with Craig Ackerman In Philadelphia this month, pharmaphorum spoke with Craig Ackerman, a partner at the Alexander Group, about launches, AI best practices, and more.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.